TrueSignature Archives - Biognosys

Biognosys’ TrueSignature targeted proteomics platform offers a robust CRO service for precise protein quantification across diverse biological matrices and species, offering several key advantages:

Unmatched specificity
Reference peptides enable simultaneous monitoring of endogenous
targets and internal standards, ensuring assay specificity across diverse
matrices.

Proteotypic peptide selection
Eliminates the need for antibodies, allowing precise monitoring of protein
variants such as mutations, truncations and isoforms.

Multiplexing flexibility
Fully customizable assay panels can accommodate up to 50 targets of
interest.

Application in clinical settings
Automated sample preparation and Good Clinical Practice (GCP)-
compliant workflows ensure suitability for clinical studies.

Targeted Protein Degradation (TPD) is an emerging pharmaceutical modality that enables the modulation of proteins traditionally considered undruggable by conventional small molecules. TPD strategies, such as molecular glue degraders and proteolysis-targeting chimeras (PROTACs), hijack the cellular ubiquitin-proteasome system to selectively degrade pathogenic proteins.

High-content proteomics profiling is a powerful tool to identify targets and confirm degradation by quantifying protein levels across conditions. Here, we present a two-step workflow comprising of automated sample preparation for bottom-up proteomics and subsequent heavy-labeled reference peptide spike-in coupled to LC-MS acquisition. This workflow enables both global proteome profiling and targeted quantification of proteins of interest (POIs), facilitating comprehensive analysis of TPD compound effects. We demonstrate its utility by screening ten preclinical and clinical-stage molecular degraders targeting six disease-relevant proteins.

In January, we announced our new strategic partnership with Bruker to broaden access to our leading proteomics services & tools for biopharma and #biomarker customers.

In this exciting SpotLight episode, Biognosys’ CEO Oliver Rinner and Rohan Thakur, President of the Bruker Life-Science Mass Spectrometry division, discuss the many synergies of the new alliance and give an outlook of what the future might hold.

 

Poster presented at IMSC 2022

Presenter: Simonas Savickas

Session: Poster Session B
Date: August 31 and September 1

Various studies in the last years have shown that using SRM/MRM has the potential to identify hundreds of biomarker candidates in one study (Mermelekas, 2015). However, panel development remains asignificant bottleneck in the adoption of targeted proteomics.

Contact